December 25, 2019
Gilead Sciences has tapped Eisai, a maven in inflammatory diseases, as a partner to jointly commercialize its oral JAK1 inhibitor filgotinib in Japan for its approval-pending use for rheumatoid arthritis (RA) and other potential future indications. The two companies said...read more